Antibody levels against GLURP R2, MSP1 block 2 hybrid and AS202.11 and the risk of malaria in children living in hyperendemic (Burkina Faso) and hypo-endemic (Ghana) areas by Adu, Bright et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Antibody levels against GLURP R2, MSP1 block 2 hybrid and AS202.11 and the risk of
malaria in children living in hyperendemic (Burkina Faso) and hypo-endemic (Ghana)
areas
Adu, Bright; Cherif, Mariama K; Bosomprah, Samuel; Diarra, Amidou; Arthur, Fareed K. N.;
Dickson, Emmanuel K.; Corradin, Giampietro; Cavanagh, David R; Theisen, Michael; Sirima,
Sodiomon B; Nebie, Issa; Dodoo, Daniel
Published in:
Malaria Journal
DOI:
10.1186/s12936-016-1146-4
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Adu, B., Cherif, M. K., Bosomprah, S., Diarra, A., Arthur, F. K. N., Dickson, E. K., ... Dodoo, D. (2016). Antibody
levels against GLURP R2, MSP1 block 2 hybrid and AS202.11 and the risk of malaria in children living in
hyperendemic (Burkina Faso) and hypo-endemic (Ghana) areas. Malaria Journal, 15(1), [123].
https://doi.org/10.1186/s12936-016-1146-4
Download date: 03. Feb. 2020
Adu et al. Malar J  (2016) 15:123 
DOI 10.1186/s12936-016-1146-4
RESEARCH
Antibody levels against GLURP R2, 
MSP1 block 2 hybrid and AS202.11 and the risk 
of malaria in children living in hyperendemic 
(Burkina Faso) and hypo-endemic (Ghana) areas
Bright Adu1†, Mariama K. Cherif2,3†, Samuel Bosomprah4, Amidou Diarra3, Fareed K. N. Arthur5, 
Emmanuel K. Dickson1, Giampietro Corradin6, David R. Cavanagh7, Michael Theisen8, Sodiomon B. Sirima3, 
Issa Nebie3* and Daniel Dodoo1*
Abstract 
Background: Differences in parasite transmission intensity influence the process of acquisition of host immunity to 
Plasmodium falciparum malaria and ultimately, the rate of malaria related morbidity and mortality. Potential vaccines 
being designed to complement current intervention efforts therefore need to be evaluated against different malaria 
endemicity backgrounds.
Methods: The associations between antibody responses to the chimeric merozoite surface protein 1 block 2 hybrid 
(MSP1 hybrid), glutamate-rich protein region 2 (GLURP R2) and the peptide AS202.11, and the risk of malaria were 
assessed in children living in malaria hyperendemic (Burkina Faso, n = 354) and hypo-endemic (Ghana, n = 209) 
areas. Using the same reagent lots and standardized protocols for both study sites, immunoglobulin (Ig) M, IgG 
and IgG sub-class levels to each antigen were measured by ELISA in plasma from the children (aged 6–72 months). 
Associations between antibody levels and risk of malaria were assessed using Cox regression models adjusting for 
covariates.
Results: There was a significant association between GLURP R2 IgG3 and reduced risk of malaria after adjusting age 
of children in both the Burkinabe (hazard ratio 0.82; 95 % CI 0.74–0.91, p < 0.0001) and the Ghanaian (HR 0.48; 95 % CI 
0.25–0.91, p = 0.02) cohorts. MSP1 hybrid IgM was associated (HR 0.85; 95 % CI 0.73–0.98, p = 0.02) with reduced risk 
of malaria in Burkina Faso cohort while IgG against AS202.11 in the Ghanaian children was associated with increased 
risk of malaria (HR 1.29; 95 % CI 1.01–1.65, p = 0.04).
Conclusion: These findings support further development of GLURP R2 and MSP1 block 2 hybrid, perhaps as a fusion 
vaccine antigen targeting malaria blood stage that can be deployed in areas of varying transmission intensity.
Keywords: Malaria, Antibodies, GLURP R2, MSP1 block 2 hybrid, AS202.11, Hyperendemic, Hypo-endemic, 
Transmission intensity
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Background
Falciparum malaria remains a significant cause of infant 
mortality and morbidity in many parts of the world 
especially in sub-Saharan Africa even though decreas-
ing trends of transmission intensity have been reported 
[1–3]. An efficacious blood stage vaccine against malaria 
that remains potent in different transmission settings 
would greatly contribute to reducing the disease bur-
den among endemic populations. However, the putative 
antigenic targets of protective immunity against malaria 
have remained elusive and several parasite proteins have 
been implicated, most of which are polymorphic. Anti-
body responses targeting polymorphic malaria parasite 
surface proteins have been associated with reduced risk 
of malaria [4–6]. This may partly explain the need for 
repeated infections in the acquisition of natural protec-
tive immunity among adults living in endemic popu-
lations [7]. While polymorphic antigens may not be 
the most ‘attractive’ candidates for vaccine design, it 
is thought that such a vaccine, if successful, could elicit 
a broad spectrum of immune repertoire particularly in 
children and other vulnerable groups [8]. The merozo-
ite surface protein (MSP)1 is synthesized in a precursor 
form as a 195kD protein and proteolytically cleaved into 
fragments prior to schizont rupture [9]. The carboxy-ter-
minal portion is largely conserved with only a few single 
nucleotide polymorphisms (SNPs) [10] while the amino-
terminal portion has the most polymorphic region, 
termed block 2 [11, 12]. Antibody responses directed 
against the block 2 region have been associated with 
reduced risk of clinical malaria in different populations 
[5, 13, 14]. A synthetic MSP1 block 2 construct, based 
on several polymorphic variants found in natural Plas-
modium falciparum isolates was designed and fused with 
the relatively conserved block 1 sequence of MSP1 to 
form the MSP1 block 2 hybrid [8]. This synthetic protein 
was immunogenic in experimental animal models and 
was recognized by sera from Burkinabe and Ghanaian 
children naturally exposed to the parasite [8]; however, 
studies assessing anti-MSP1 block 2 hybrid antibodies in 
relation to the risk of malaria in longitudinal cohorts is 
currently lacking.
The glutamate rich protein-region 2 (GLURP R2) is 
from the carboxy-terminal repeat region of GLURP and 
is the most immunodominant portion of the protein 
[15]. Compared to the amino terminal GLURP R0 region, 
which has been extensively studied [16, 17] and forms 
part of the GMZ2 candidate vaccine [18] presently in 
phase 2b clinical trials, GLURP R2 has been less studied. 
GLURP R2 contains at least two B cell epitopes and elicits 
antibodies capable of inhibiting malaria parasite growth 
in vitro in cooperation with monocytes [19]. Importantly, 
anti-GLURP R2 antibodies were associated with reduced 
risk of symptomatic malaria infection in Burkinabe [20] 
and Ghanaian [21] children. Alpha (α) helical coiled 
motifs in malaria antigens, such as MSP3 and MSP6, 
are important oligomerization sub-units and targets of 
malaria protective antibodies [22, 23]. When separated 
from the whole protein, α-helical coiled motifs readily 
fold into the same stable oligomeric structure [24]. Thus, 
such motifs could potentially be fused to other antigenic 
targets of malaria protective antibodies to form chimeric 
proteins capable of eliciting broader spectrum immune 
response. The peptide AS202.11 (PF11 0424) (described 
elsewhere [25]) is an α-helical coiled motif. Antibody 
responses to this peptide showed a modest association 
with reduced risk of clinical malaria in children resident 
in the Kilifi district of Kenya [25]. This study successfully 
evaluated the associations between antibody responses 
against GLURP R2, MSP1 block 2 hybrid and the pep-
tide AS202.11 and the risk of malaria in two populations 
(Burkina Faso and Ghana) with different malaria trans-
mission intensities.
Methods
Ethics statement
The Burkina Faso study was approved by the Ethical 
Committee for Biomedical Research of the Ministry of 
Health of Burkina Faso, while in Ghana, the study was 
approved by the Institutional Review Board of Noguchi 
Memorial Institute for Medical Research (NMIMR) of 
the University of Ghana, Accra. At both study sites, writ-
ten informed consent was given by the parent or guard-
ian of children prior to their enrolment into the study.
Study sites
Burkina Faso: Balonghin–Sapone
The Sapone health district is 50  km southeast of Oua-
gadougou, the capital city of Burkina Faso. The area has 
been described elsewhere [26]. The climate in this area is 
characteristic of the Sudanese savannah, with a dry sea-
son from November to May (low transmission season) 
and a rainy season from June to October (high transmis-
sion season). Malaria transmission is markedly seasonal; 
most transmission occurs during the rainy season. The 
entomological inoculation rate (EIR) in Balonghin was 
estimated at 0.3 infective bites per person per month 
during the dry season and 44.4 infective bites per person 
per month during the rainy seasons [26]. Plasmodium 
falciparum is the predominant malaria parasite, account-
ing for more than 95 % of infections.
Ghana: Asutsuare–Damgbe West
The study was conducted in Asutsuare about 120  km 
northeast of Accra and five neighbouring villages of the 
Damgbe West district in the southeastern part of Ghana, 
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described elsewhere [27]. Briefly, rainfall is usually con-
tinuous throughout the year but highest from June to 
August and moderate in November and December just 
before the beginning of the dry season. Thus, there are 
two seasonal peaks of malaria transmission correspond-
ing to the wet seasons but also relatively minimal trans-
mission throughout the remaining times of the year. 
Malaria incidence in Asutsuare was 8.9  % in 2009 [27], 
the year of the present study. However, the incidence rate 
of clinical malaria was reported as 106.6 per 1000 popu-
lation in Dodowa a suburb of about 44 km away in 1992 
[28]. About 98 % of malaria cases in the area are due to P. 
falciparum infection while Plasmodium ovale and Plas-
modium malariae account for the remaining [29].
Study design, sample collection and follow‑up
In Burkina Faso, 525 children aged 6–60  months inclu-
sive were enrolled in the study while the Ghanaian 
cohort consisted of 600 individuals aged one to 29 years. 
However, for comparison purposes, the current study 
excluded the older aged Ghanaians and only included 
209 Ghanaian children (aged 12–72  months) and the 
354 Burkinabe children who completed the follow-up. At 
both study sites, participants were enrolled prior to the 
high malaria transmission season (Fig.  1). During base-
line (enrolment) sampling at each site, 5  ml (or about 
1 ml for younger children) EDTA-anticoagulated venous 
blood was collected from each child and centrifuged. 
Plasma obtained was aliquoted and stored at −20  °C 
for immunological analyses. Thick and thin film blood 
slides (TTBS) were obtained for microscopy diagnosis 
of malaria. The ensuing active case detection during the 
longitudinal follow-up was either twice weekly (Burkina 
Faso) or weekly (Ghana). The follow-up duration was 
39  weeks for the Burkinabe and 36  weeks for the Gha-
naian cohorts, respectively. Axillary temperature was 
measured on each visit of a child by a trained field assis-
tant and children with fever, defined as axillary temper-
ature  >37.5  °C or a history of fever reported within the 
last 24  h. In Burkina Faso, malaria rapid diagnostic test 
(RDT) was performed and children with positive results 
were referred to the nearest health centre for appro-
priate treatment. In Ghana, children with fever were 
referred without RDT, to the health centres and TTBS 
made. Children diagnosed with malaria were treated 
with artemisinin-based combination therapy which was 
the standard treatment for malaria in both countries at 
the time of the study. At both study sites, clinical malaria 
was defined as axillary temperature ≥37.5 °C (or history 
of fever in the last 24 h preceding the visit) and parasite 
density ≥5000/μl with at least one other sign of malaria 
such as vomiting, diarrhoea or malaise. Parasite density 
determination by microscopy was determined as previ-
ously described [26].
Malaria antigens
The recombinant GLURP R2 (amino acids 705-1178) of 
the carboxy-terminal repeat region expressed in Escher-
ichia coli [15]. The MSP1 hybrid (described in detail 
elsewhere, [8]) was from a synthetic gene designed to 
incorporate sequences derived from one version of 
the semi-conserved block 1 and all three serotypes 
of the highly polymorphic block 2 of MSP1. Briefly, 
the upstream sequence corresponds to the block 1 
sequence from K1-type MSP1 and is followed by arti-
ficially designed sequences which include the three 
main variants of the block 2 found in over 150 labora-
tory and field isolates. The RO33 type contains minimal 
Fig. 1 Site-specific transmission seasons and period of cohort enrolment. BF Burkina Faso, GH Ghana
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point mutations only while the other two types (K1 and 
MAD20) are characterized by unique, serotype-specific 
flanking sequences, each containing different sets of trip-
eptide repeats which differ within each serotype by both 
order and number. The resulting MSP-1 block 2 hybrid 
construct of 348 amino acids in length (in a pET24a 
expression vector) was expressed as a 31  kDa untagged 
protein in the E. coli BLR (DE3) pLysS strain. The syn-
thetic peptide, AS202.11-(QLEEKTKQYNDLQNNMKT
IKEQNEHLKNKFQSMGK) used in the study has been 
described in detail elsewhere [30].
Antigen‑specific antibody measurement
Antigen-specific antibody levels were measured using the 
Afro Immuno Assay (AIA) ELISA protocol [16, 31] with 
modifications. Briefly, 96-well microtitre ELISA plates 
(Maxisorp Nunc, Denmark) were coated with antigens 
at 1.0 μg/ml (GLURP R2 and MSP1 hybrid) or 5.0 μg/ml 
(AS202.11) in 1X PBS (pH 7.04). Coated plates were kept 
in a refrigerator at 2–8 °C overnight. Plates were blocked 
(PBS with 5 % milk powder, 0.1 % Tween-20) and incu-
bated at room temperature (RT) in a humidified chamber 
for 1  h. Plasma samples diluted at 1:200 in serum dilu-
tion buffer (PBS with 2.5 % milk powder, 0.1 % Tween-20 
and 0.02 % Na-azide) were added in duplicates and incu-
bated 2 h at RT. To control for inter-assay and day-to-day 
variations each ELISA plate included a reference curve 
obtained by a two-fold titration of pool of hyper immune 
plasma. In addition, each plate included a negative con-
trol sample (a pool of plasma sample from Danish blood 
donors never exposed to malaria), a positive control sam-
ple (plasma from clinically semi-immune adults obtained 
from the Korle-Bu blood bank, Accra) and a buffer blank. 
The dilutions for the horseradish peroxidase (HRP) con-
jugated secondary antibodies used in the assays were: 
goat anti-human IgG (γ) (H10007) (Invitrogen Corpo-
ration, CA, USA) (1:80,000) and goat anti-human IgM 
(μ) (H15007) (Invitrogen) (1:3000). The IgG sub-classes 
were detected using HRP-conjugated sheep anti-human 
IgG1 (AP006) (1:5000), IgG2 (AP007) (1:2000), IgG3 
(AP008) (1:10,000) and IgG4 (AP009) (1:1000) antibod-
ies (The Binding Site Group Ltd, UK), respectively. These 
were added at 100 μl/well to respective plates and incu-
bated for 1 h at RT. Plates were washed (PBS with 0.1 % 
Tween-20 and 0.5 M NaCl) four times between consecu-
tive steps. Bound secondary antibodies were quantified 
using TMB (3,3′,5,5′-tetramethylbenzidine) substrate 
(Kem-En-Tec Diagnosis A/S, Taastrup, Denmark) and 
incubated in the dark for 30  min. Optical density (OD) 
was read at 450 nm. The OD values for the test samples 
were converted into antibody units (AU) with the stand-
ard reference curves generated for each ELISA plate 
using a four-parameter curve-fit Microsoft Excel-based 
application (ADAMSEL b040, Ed Remark© 2009). Sam-
ples were re-tested if the coefficient of variation between 
duplicate absorbance values were higher than 15  % and 
plates were also re-tested if the R2 value of the standard 
curve was less than 97 %. The same ELISA protocols, rea-
gents lot and batch of positive and negative control sam-
ples were used at both study sites.
Statistical analysis
Individuals were categorized as either responders or non-
responders for each antigen based on IgG cut-off value 
calculated by the mixture model [32]. Mixture models 
have been reported extensively in characterising individ-
ual’s exposure status in infectious diseases [33–35] and 
have been applied in malaria research [36–38]. Briefly, 
normalized (log 10 transformation) IgG AU for each anti-
gen was fitted as the sum of two Gaussian distributions by 
maximum likelihood methods. The cut-off for responder 
was defined as mean AU of the narrow distribution (non-
responder population) plus three standard deviations. 
The AS202.11 antigen, IgG sub-class levels were too low 
in both cohorts during protocol optimization and hence 
these were not measured in the final ELISA analysis. For 
each antigen, scatter plot and univariate linear regression 
analyses were used to assess the relationship between 
antibody levels and age. Cumulative malaria incidence 
and 95  % confidence interval estimated by the Kaplan–
Meier method were defined as the proportion of children 
with at least one episode of clinical malaria by the end 
of surveillance period. Incidence rate was defined as the 
ratio of the total number of clinical malaria episodes to 
the total child months at risk. For estimating 95 % con-
fidence interval on the incidence rates, standard errors 
were calculated using the method described by Stukel 
et al. [39], which allows for repeated episodes in the same 
child. This assumes rates are constant over time. Cox 
regression including all episodes of clinical malaria, and 
using a robust estimate of the standard error that takes 
into account the correlation among multiple episodes per 
person was used to estimate the rate ratio. Antibody level 
was modelled as continuous variable transformed to log 
base 10 so that rate ratios indicate the decrease in inci-
dence rate of malaria corresponding to a ten-fold increase 
in baseline antibody levels. Age, baseline parasitaemia 
and gender were considered a potential confounder and 
were adjusted for in the analysis. Age was modelled as a 
categorical variable with four levels: 6–23, 24–35, 36–47, 
and 48–72 months. Cases occurring within 14 days of the 
start of treatment for malaria were assumed to be relapse 
of the original case and were not counted. The time at 
risk for each child was calculated based on date of start of 
follow-up and date of end of the study or until the child 
was censored. Both site specific and pooled analysis of 
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hazard ratios for the association between antibody levels 
and clinical malaria were performed. Stata version 10 for 
Windows (College Station, Texas, USA) and R v3.2.2 [40] 
were used for the analyses.
Results
Plasmodium falciparum infection in the study cohorts
Altogether, 563 children aged 6–72  months were 
included in the study. They comprised 354 and 209 chil-
dren from Burkina Faso and Ghana, respectively, who 
completed the entire duration of the follow-up at each 
site. The Burkinabe children (mean age =  34.2  months) 
were significantly younger than the Ghanaian children 
(mean age = 51.8 months) (p < 0.0001, Welch Two Sam-
ple t-test). No child used insecticide-treated nets (ITN) 
in the Burkinabe cohort while among the Ghanaian chil-
dren, ITN usage was 31.6 % but was not associated with 
clinical malaria (p  >  0.05, Pearson’s Chi squared test). 
Baseline parasite prevalence was higher in the Burkinabe, 
[61.9 %, (219/354)] than in the Ghanaian [2.9 %, (6/209)] 
cohort (Table  1). The cumulative incidence of malaria 
decreased with age of study participants, although this 
observation was more prominent in the Burkinabe than 
in the Ghanaian cohort (Table  1). Similarly, cumulative 
malaria incidence was lower in responders to GLURP 
R2 and MSP1 hybrid in Burkina Faso but this trend was 
not seen in the Ghanaian cohort. Malaria incidence 
among responders and non-responders to AS202.11 did 
not differ either among Burkinabe or Ghanaian chil-
dren (Table  1). The proportion of children with at least 
one episode of clinical malaria at the end of the follow-
up period was 70.7  % (95  % CI 65.8–75.3) in Burkina 
Faso and 8.6  % (95  % CI 5.5–13.3) in Ghana (Table  1). 
The number of malaria episodes per child ranged from 
nought to seven in Burkina Faso and nought to two in 
Ghana (Additional file 1: Table S1). A total of 154 (43.5 %) 
Burkinabe children experienced at least two malaria epi-
sodes while only a single child in Ghana had exactly two 
episodes (Additional file 1: Table S1).
Relationship between antibody levels and age of study 
participants
The levels of isotype IgG, IgM and IgG sub-classes 
against all three antigens (GLURP R2, MSP1 hybrid and 
AS202.11), except IgG1 and IgG4 against MSP1 hybrid, 
increased significantly (p  <  0.05) with age in children 
from Burkina Faso (Table 2). Among the Ghanaian chil-
dren, only levels IgG3 against GLURP R2 and IgM against 
all the antigens increased significantly (p  <  0.05) with 
age. The adjusted R2 values from the univariate linear 
regression analysis of antibody levels and age was gener-
ally low especially for the Ghanaian cohort (adjusted R2 
range: Burkina Faso  =  0.0013–0.16; Ghana  =  0–0.054) 
(Table 2). Except for anti-AS202.11 IgM antibody levels, 
children in the Burkinabe cohort always had higher anti-
body levels against the studied antigens than those in the 
Ghanaian cohort (Fig. 2a, b).
Antigen‑specific antibodies in relation to risk of clinical 
malaria
In the Burkinabe cohort, isotype IgG responses against 
GLURP R2 (HR 0.84; 95 % CI 0.73–0.97; p =  0.01) and 
MSP1 hybrid (HR 0.83; 95  % CI 0.70–0.98; p  =  0.03) 
were significantly associated with reduced risk of clini-
cal malaria after adjusting for age (Table  3). Of the IgG 
sub-class responses, IgG2 and IgG4 against GLURP R2 
and IgG3 against both GLURP R2 and MSP1 hybrid were 
all significantly associated with reduced risk of malaria 
(p  <  0.05) in children from Burkina Faso (Table  3). Iso-
type IgM responses against both GLURP R2 (HR 0.77; 
95  % CI 0.63–0.95; p  =  0.01) and MSP1 hybrid (HR 
0.82; 95 % CI 0.71–0.94; p = 0.01) were also significantly 
associated with reduced risk of clinical malaria in the 
Burkinabe cohort. In the Ghanaian cohort, only IgG3 
against GLURP R2 was significantly (HR 0.54; 95  % CI 
0.30–0.98; p  =  0.04) associated with decreased risk of 
malaria (Table  3). When the two cohorts were com-
bined, all GLURP R2 antibodies, except IgG1, were sig-
nificantly associated with reduced risk of malaria as was 
IgM against MSP1 hybrid (Table  3). In a final model to 
assess immunological variables independently associ-
ated with malaria, IgG3 against GLURP R2 (in both 
study sites) and IgM against MSP1 hybrid (in Burkina 
Faso only) were significantly (p  <  0.05) associated with 
reduced risk of malaria (Table 4). On the other hand, IgG 
against AS202.11 was associated with increased risk of 
clinical malaria (HR 1.29; 95 % CI 1.01–1.65; p = 0.04) in 
the Ghanaian cohort (Table 4).
Discussion
The association between antibody levels against GLURP 
R2, MSP1 block 2 hybrid and AS202.11 and the risk of 
clinical malaria was investigated in two independent 
immune-epidemiological studies conducted in malaria 
hyperendemic (Burkina Faso) and hypo-endemic 
(Ghana) populations, respectively, using the same study 
protocols and reagents lots. Overall, high levels of IgG3 
against GLURP R2 was strongly associated with reduced 
risk of clinical malaria in both Burkinabe and Ghana-
ian children despite the marked differences in malaria 
transmission intensity between these two populations. In 
Burkinabe children, IgM responses against MSP1 hybrid 
contributed significantly to reducing the risk of clini-
cal malaria while in Ghanaian children, increased levels 
of IgG against the peptide AS202.11 was associated with 
about 29  % increased risk of clinical malaria (Table  4). 
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Table 2 Relationship between antibody levels and age
Coefficient, 95 % confidence level (CI), p values and adjusted R2 values were calculated from univariate linear regression models
Burkina Faso Ghana
Antibody Antigen Coefficient (95 % CI) p value Adjusted R2 Coefficient (95 % CI) p value Adjusted R2
IgG GLURP R2 6.69 (4.10, 10.91) <0.0001 0.14 2.82 (0.97, 8.23) 0.057 0.013
MSP1-hybrid 9.28 (4.75, 18.13) <0.0001 0.11 1.56 (4.10, 5.93) 0.51 0
AS202.11 2.23 (1.33, 4.28) 0.0037 0.021 0.86 (0.35, 2.14) 0.73 0
IgG1 GLURP R2 5.55 (2.91, 10.60) <0.0001 0.069 3.09 (1.00, 9.61) 0.051 0.014
MSP1-hybrid 2.08 (0.63, 6.83) 0.23 0.0013 0.71 (0.37, 1.36) 0.3 0.0004
IgG2 GLURP R2 10.37 (6.00, 17.94) <0.0001 0.16 2.39 (0.70, 8.12) 0.16 0.0047
MSP1-hybrid 21.88 (6.98, 68.57) <0.0001 0.072 1.00 (0.28, 3.66) 1 0
IgG3 GLURP R2 6.16 (4.02, 9.43) <0.0001 0.16 2.93 (1.20, 7.16) 0.019 0.021
MSP1-hybrid 2.81 (1.85, 4.26) <0.0001 0.061 3.09 (0.90, 1.06) 0.073 0.011
IgG4 GLURP R2 2.76 (1.62, 4.71) 0.00021 0.036 8.81 (0.94, 82.24) 0.056 0.013
MSP1-hybrid 1.88 (0.96, 3.68) 0.064 0.0069 3.42 (0.62, 18.77) 0.16 0.005
IgM GLURP R2 36.64 (14.83, 90.52) <0.0001 0.15 35 (5.01, 248.77) 0.0004 0.054
MSP1-hybrid 8.76 (3.18, 24.12) <0.0001 0.045 7.62 (1.05, 55.45) 0.045 0.015
AS202.11 3.60 (1.75, 7.41) 0.00055 0.031 6.86 (1.20, 3.93) 0.031 0.018
Fig. 2 Isotype IgG and IgM and IgG sub-class levels in relation to age. a Total IgG or IgM levels against the antigens AS202.11 (top), GLURP R2 
(middle) and MSP1 hybrid (bottom), respectively. b IgG1, IgG2, IgG3, or IgG4 levels against the antigens GLURP R2 (left) and MSP1 hybrid (right), 
respectively. Linear regression lines are shown for each antigen specific antibody level for each site
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In previous studies, IgG against AS202.11 was found to 
increase with age and associated with protection from 
malaria of Kenyan children [25] living in an area of high 
malaria transmission (EIR ranging from 20 to 100 infec-
tive bites per year [41]). Here, malaria incidence in the 
Burkinabe cohort was very high, and although AS202.11 
IgG and IgM antibodies clearly increased with age, none 
was associated with protection against malaria. In addi-
tion, the weak IgG responses to AS202.11 in the malaria 
hypo-endemic population of Ghana, with its subse-
quent association with increased malaria risk, suggests 
it may rather be a marker of exposure in the studied 
populations.
In most malaria-endemic populations, intensified 
transmission prevention measures such as use of ITNs, 
indoor residual spraying and effective therapeutics are 
rapidly changing the landscape of malaria epidemiol-
ogy [42, 43]. Malaria incidence in the Burkinabe cohort 
was more than eight-fold higher than in the Ghana-
ian cohort possibly due to the lack of ITN usage in the 
former. It may also be due to the risk of malaria being 
higher in younger children living in communities where 
transmission intensity is high [1, 44, 45]. Thus, the Gha-
naian cohort consisting of older children living in a 
malaria hypo-endemic region was already at a much 
lower risk of getting malaria. In populations with steady 
and high malaria transmission intensity, acquired immu-
nity to clinical malaria develops rapidly with frequency 
of exposure to the parasite and age [45, 46]. This may 
be due to acquisition of a broad spectrum of protective 
antibodies in such populations early in life. High inten-
sity of transmission may also be necessary for sustaining 
Table 3 Association between antibody levels and clinical malaria among children from Burkina Faso and Ghana
Crude hazard ratios (HR) as well as age-adjusted HR and p values are shown, indicating the ratio of malaria hazard rates associated with a tenfold increase in baseline 
antibody level
a 95 % CI were estimated using Cox regression model with robust standard error to adjust for clustering in children
b Stratified estimates (i.e., equal coefficients across sites but with baseline hazard unique to each site)
Antibody Antigens Burkina Faso Ghana Overall
Crude HR 
(95 % CI)
HR 
adjusted 
for age 
(95 % CI)a
p value 
for adjusted 
HR
Crude HR 
(95 % CI)
HR 
adjusted 
for age 
(95 % CI)a
p value 
for adjusted 
HR
Crude HR 
(95 % CI)b
HR 
adjusted 
for age 
(95 % CI)b
p value 
for adjusted 
HR
IgG GLURP R2 0.75 (0.66, 
0.85)
0.84 (0.73, 
0.97)
0.01 0.77 (0.44, 
1.34)
0.73 (0.41, 
1.30)
0.28 0.75 (0.66, 
0.85)
0.85 (0.74, 
0.97)
0.02
MSP1-
hybrid
0.73 (0.61, 
0.87)
0.83 (0.70, 
0.98)
0.03 1.40 (0.64, 
3.08)
1.19 (0.57, 
2.50)
0.64 0.75 (0.63, 
0.89)
0.85 (0.72, 
1.01)
0.06
AS202.11 0.93 (0.82, 
1.05)
0.97 (0.87, 
1.09)
0.65 1.37 (0.89, 
2.11)
1.15 (0.85, 
1.56)
0.38 0.93 (0.82, 
1.06)
0.98 (0.88, 
1.10)
0.76
IgG1 GLURP R2 0.86 (0.73, 
1.00)
0.97 (0.82, 
1.14)
0.68 0.93 (0.47, 
1.85)
0.91 (0.45, 
1.86)
0.8 0.86 (0.74, 
1.00)
0.97 (0.83, 
1.14)
0.69
MSP1-
hybrid
0.96 (0.75, 
1.23)
0.96 (0.77, 
1.21)
0.76 1.22 (0.78, 
1.92)
1.03 (0.67, 
1.58)
0.91 1.00 (0.80, 
1.25)
1.01 (0.82, 
1.24)
0.94
IgG2 GLURP R2 0.74 (0.65, 
0.83)
0.85 (0.75, 
0.96)
0.01 1.45 (0.71, 
2.97)
1.24 (0.64, 
2.43)
0.52 0.74 
(0.66,0.84)
0.86 (0.76, 
0.98)
0.02
MSP1-
hybrid
0.73 (0.59, 
0.91)
0.87 (0.70, 
1.08)
0.2 1.19 (0.47, 
3.01)
1.17 (0.51, 
2.67)
0.72 0.74 (0.60, 
0.92)
0.89 (0.72, 
1.10)
0.27
IgG3 GLURP R2 0.73 (0.66, 
0.81)
0.81 (0.73, 
0.90)
<0.0001 0.48 (0.25, 
0.93)
0.54 (0.30, 
0.98)
0.04 0.73 (0.66, 
0.81)
0.81 (0.73, 
0.90)
<0.0001
MSP1-
hybrid
0.85 (0.78, 
0.93)
0.91 (0.84, 
0.99)
0.04 0.82 (0.38, 
1.77)
0.83 (0.33, 
2.08)
0.69 0.86 (0.78, 
0.94)
0.92 (0.84, 
1.00)
0.05
IgG4 GLURP R2 0.79 (0.68, 
0.92)
0.85 (0.73, 
0.98)
0.02 1.18 (0.31, 
4.57)
1.30 (0.38, 
4.43)
0.68 0.79 (0.68, 
0.92)
0.85 (0.73, 
0.98)
0.02
MSP1-
hybrid
0.95 (0.83, 
1.09)
0.97 (0.85, 
1.11)
0.65 1.14 (0.32, 
4.03)
0.82 (0.29, 
2.31)
0.7 0.95 (0.83, 
1.09)
0.98 (0.86, 
1.11)
0.73
IgM GLURP R2 0.66 (0.55, 
0.79)
0.77 (0.63, 
0.95)
0.01 0.70 (0.14, 
3.57)
1.14 (0.24, 
5.40)
0.87 0.66 (0.55, 
0.79)
0.78 (0.64, 
0.95)
0.02
MSP1-
hybrid
0.72 (0.63, 
0.84)
0.81 (0.70, 
0.94)
0.01 1.42 (0.25, 
8.07)
1.68 (0.36, 
7.93)
0.51 0.73 (0.63, 
0.84)
0.82 (0.70, 
0.95)
0.01
AS202.11 0.86 (0.74, 
0.99)
0.92 (0.80, 
1.05)
0.23 0.58 (0.23, 
1.45)
0.70 (0.26, 
1.90)
0.49 0.85 (0.74, 
0.98)
0.92 (0.80, 
1.06)
0.23
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malaria-specific antibodies at high levels and functional-
ity [45, 47]. Conversely, with a decline in malaria trans-
mission intensity, as was evident in the Ghanaian cohort, 
prolonged exposure over relatively longer periods may be 
necessary in building a sufficient repertoire of protective 
antibodies [45]. This may explain why antibody associa-
tions with protection were more distinct in the Burkinabe 
children than in the Ghanaian children. In the antibody 
association with age models, the low R2 values observed, 
particularly for the Ghanaian cohort, suggests in areas of 
very low malaria transmission, age alone may not ade-
quately explain acquisition of malaria-specific antibodies.
In previous studies, GLURP R2 IgG was associated 
with protection against malaria in Burkinabe [20] and 
Myanmar [48] children. The present study supports these 
finding since high titres of IgG antibodies to GLURP R2 
were significantly associated with reduced risk of malaria 
with IgG3 showing the strongest effect in both cohorts. 
The association of GLURP R2 IgG2 titres with reduced 
risk of malaria in the Burkinabe cohort may be due to 
the observation that IgG2 binds with high affinity to Fc 
gamma receptor IIA-131H (FcγRIIA-131H) allele on 
immune cells of individuals expressing this variant [49–
51]. Although FcγRIIA was not genotyped in the present 
study, other studies in the same district in Burkina Faso 
reported FcγRIIA-131H-allele frequency to be 28.6 % in 
the population [52]. Thus, individuals with this FcγRIIA-
131H polymorphism could benefit from GLURP R2 
IgG2 mediated cellular effector functions that may afford 
protection against malaria. MSP1 block 2 epitopes have 
been shown to be important targets of antibodies asso-
ciated with protection from clinical malaria [6, 13, 14]. 
Plasmodium falciparum diversity at the Ghanaian site 
is unknown, however, the K1 and MAD 20 allelic fami-
lies of msp1 have been shown to be the most prevalent 
in Balonghin, Burkina-Faso [53]. Here, the MSP1 hybrid 
used was specifically designed to incorporate most of 
the block 2 allelic variants purported to be targets of 
protective antibodies against malaria [8]. Moreover, the 
present study is the first to show antibody responses 
against the MSP1 block 2 hybrid to be associated with 
reduction in risk of symptomatic P. falciparum infec-
tions. Both GLURP R2 and MSP1 block 2 have been 
shown to elicit antibodies capable of inhibiting parasite 
growth in vitro in the monocyte-dependent mechanism, 
antibody-dependent cellular inhibition (ADCI) [19, 54]. 
This may explain the strong association with protection 
observed with IgG3 antibodies to these antigens since 
IgG3 is considered superior to IgG1 in parasite clear-
ance [55]. Antigen-specific IgM antibody responses are 
usually associated with primary infection and not so 
commonly with protection from disease. However, pre-
vious studies in both Ghana [16] and Burkina Faso [56] 
have found association with protection and IgM anti-
bodies to MSP1 and GLURP. In the current study, IgM 
against MSP1 hybrid was associated with reduced risk 
of malaria in Burkinabe children, supporting the view 
that the function of IgM may complement IgG in anti-
malarial immunity [57]. Although anti-MSP1 hybrid IgM 
levels were similar in both cohorts, the association with 
protection was only seen in the Burkina Faso cohort. 
This may reflect differences in epitope specificity and/
or avidity of IgM responses under the different malaria 
transmission intensities in the two cohorts. The possible 
Table 4 Adjusted hazard ratios for  immunological variables independently associated with  malaria risk in  the final 
model
Hazard ratios (HR) indicates the ratio of malaria hazard rates associated with a ten-fold increase in baseline antibody level
Sites Immunological/age variables Adjusted HR (95 % CI) Wald p value
Burkina Faso GLURP R2 IgG3 (values transformed to log base 10) 0.82 (0.74, 0.91) p < 0.0001
MSP1-hybrid IgM (values transformed to log base 10) 0.85 (0.73, 0.98) p = 0.02
Age group (months)
 6–23 1 p < 0.0001
 24–35 1.12 (0.91, 1.38)
 36–47 0.82 (0.62, 1.07)
 48–60 0.44 (0.31, 0.63)
Ghana GLURP R2 IgG3 (values transformed to log base 10) 0.48 (0.25, 0.91) p = 0.02
AS202.11 IgG (values transformed to log base 10) 1.29 (1.01, 1.65) p = 0.04
Age group (months)
 6–23 1 p < 0.01
 24–35 0.14 (0.04, 0.48)
 36–47 0.14 (0.04, 0.48)
 48–72 0.19 (0.07, 0.55)
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mechanism(s) by which IgM could mediate protection 
in malaria remains unclear and several hypotheses have 
been proposed [58]. It has been suggested that IgM with 
its pentameric structure capable of binding ten anti-
genic sites may play a role in blocking merozoite invasion 
of erythrocytes through agglutination or may mediate 
antibody-dependent phagocytic mechanisms [56] or 
complement-mediated anti-parasitaemic processes [58]. 
Functional studies investigating the effect of malaria-spe-
cific IgM antibodies on parasite growth will be needed to 
elucidate the possible mechanism by which IgM mediates 
protection against malaria.
Conclusion
This study corroborates findings from previous studies 
associating GLURP R2 as an important target for pro-
tective antibodies against malaria. The results show for 
the first time, that antibodies against the chimeric MSP1 
block 2 hybrid are associated with reduced risk of malaria 
in a hyperendemic population. The findings support the 
further development of both GLURP R2 and MSP1 block 
2 hybrid as important blood stage vaccine candidates that 
may be deployed in children living in areas of different 
malaria endemicity. These may be most effective as a sin-
gle fused vaccine antigen rather than as individual sub-
unit vaccines.
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